In the face of a potential rate hike by the Federal Reserve, and the presidential conventions, where should you put your money? John Augustine, The Huntington Trust chief investment officer, and Brad McMillan, Commonwealth Financial Network chief investment officer, share their strategies. » Read More
People complaining about how risky the stock market is ought to take a look at the so-called safety of today's bond market.
Jim Cramer wasn't freaked out by this bold event in the oil patch.
Jim Cramer lays out his game plan for Brexit action next week, and has his eye on black gold to hold the key on when to move.
The "FMHR" traders discuss the biotech and pharmaceuticals trade and give their best bets for stocks.
As the world's largest cancer research conference gets underway, here's how to play the stocks.
CNBC's Meg Tirrell reports on what bio-pharma breakthroughs to expect out of this year's ASCO conference, and the "FMHR" traders weigh in on the biotech sector.
Richard Ross, Managing Director and Head of Technical Analysis at Evercore ISI, takes a technical look at three stocks he says are about to break out.
Jim Cramer sees signs everywhere that the worst is over for pharma.
Jim Cramer sees signs everywhere that the worst is over for pharma. He goes down his playbook of pharma signs, and how to play it.
Some 30 American companies were recognized for their efforts to boost diversity and inclusion.
It's the busiest earnings week of the quarter. The HR experts give a preview
The FMHR traders reveal their final trades during this busy earnings week.
Jim Cramer provides his opinion on how to diversify various investor portfolios, including the great FB vs AAPL conundrum.
David Kostin, Goldman Sachs Chief U.S. Equity Strategist, talks about the current state of the markets and the risks for first quarter earnings.
Jim Cramer details how Washington has set out to stop the American investor.
Jim Cramer rattles off his take on caller favorite stocks, including this popular pharmaceutical stock that has Cramer as a buyer.
Mad Money host Jim Cramer believes presidential politics will have no impact on this high-profile stock.
"Halftime Report" trader Pete Najarian bought shares of a pharma giant on Wednesday after spotting unusual options activity.
Jim Cramer admitted he was totally wrong about this stock. He is now a believer, and thinks you should be, too.
The FMHR traders take their positions on four stocks making news today, including Bristol-Myers moving higher after Barron's said the stock could rise 25 percent in 2016.